Skip to main content

New Products

  • Manis go mobile

    NEW YORK — Want to flaunt the results of your at-home mani?

    Mani Diaries is a free iPhone app that allows users to track, manage and share their manicures and pedicures. It is basically social media for nails.

  • Aussie partners with Nickelodeon for brand's first-ever licensed product line

    CINCINNATI — Procter & Gamble hair care brand Aussie and Nickelodeon have partnered on a new hair care collection for kids inspired by the preschool series “Dora the Explorer.”

    “Nickelodeon is delighted to partner with Aussie Kids to create their first-ever licensed hair care line,” stated Samantha Kanter, VP packaged goods, Nickelodeon Consumer Products. “The collection allows Dora fans to experience their favorite explorers in a whole new way by making bath time fun and interactive for kids and parents everywhere.”

  • Creme of Nature creates new plant-derived relaxer system

    JACKSONVILLE, Fla. — Hair care manufacturer Creme of Nature has announced that it is launching Straight from Eden, a new relaxer system that utilizes a straightening creme that is 100% derived from plants to make chemical straightening gentler on hair for better management with less dryness, damage and hair breakage. The product will be in stores beginning this month.

  • Virgin Pulse launches wearable activity tracking device

    FRAMINGHAM, Mass. — Virgin Pulse on Tuesday introduced Virgin Pulse Max, an engagement and activity tracking device, as well as a new mobile app, Virgin Pulse Mobile. Max directly integrates into the Virgin Pulse software platform, enabling users to create personalized challenges based on individual program goals and track activity such as daily steps, calories burned, distance covered and active minutes of exercise. 

  • Daiichi Sankyo hopes to get FDA nod for anti-clotting drug

    PARSIPPANY, N.J. — Japanese drug maker Daiichi Sankyo is seeking Food and Drug Administration approval for a once-daily tablet to reduce the risk of stroke in patients with atrial fibrillation and treatment of other conditions.

    Daiichi Sankyo announced the submission of a new drug application for Savaysa (edoxaban). The company also is hoping to get the FDA's approval for the pill as a treatment for deep vein thrombosis and pulmonary embolism, as well as preventing the recurrence of symptomatic venous thromboembolism.

  • A&D Medical launches Wellness Connected platform

    LAS VEGAS — A&D Medical on Tuesday announced the release of its next generation Wellness Connected, a secure, flexible platform to help people increase physical activity and manage their health.

    “Designed to address the demands of corporate and consumer wellness markets, the Wellness Connected platform combines the company’s new Bluetooth Smart-enabled medical devices, A&D Connect mobile app and cloud service to give individuals and organizations the tools they need to track progress toward healthy living goals.

  • FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga

    SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by Bristol-Myers Squibb and AstraZeneca for treating Type 2 diabetes, the agency said Wednesday.

    The FDA announced the approval of Farxiga (dapagliflozin) tablets, designed for use with exercise and dietary adjustments to control blood sugar. Type 2 diabetes affects about 24 million people in the United States, accounting for more than 90% of diabetes cases.

  • Nutra Pharma ships initial product orders of Nyloxin to MyNyloxin

    CORAL SPRINGS, Fla. — Nutra Pharma on Tuesday announced that they have begun shipping the initial product orders to MyNyloxin, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter pain reliever, Nyloxin, in the network marketing channel. 

X
This ad will auto-close in 10 seconds